Introduction
Skeletal muscle dierentiation represents a co-ordinated series of events whereby mononucleate myoblasts withdraw from the cell division cycle, align, elongate and fuse to constitute multinucleated myotubes. In vitro, myoblasts can be induced to dierentiate by switching the cells into medium containing low concentration of serum. In contrast, treating myoblasts with serum or growth factors prevents dierentiation. Mitogen-activated protein kinase (MAPK) cascades transduce extracellular stimuli into intracellular pathways to regulate various cellular functions such as proliferation and dierentiation (Marshall, 1995) . Three major MAPK families have been described including the extracellular signal regulated kinases (ERK), the stress-activated Jun kinases and the p38 kinases. In the classical MAPK pathway, Ras protein activates protein kinases of the Raf family (Tzivion et al., 1998) . After activation, Raf phosphorylates the dual speci®c MAP kinase kinase protein (MEK) which in turn phosphorylates MAP kinases (ERK1 and ERK2). Other eectors can also contribute to MEK and ERK activation including the catalytic subunit of phosphatidylinositol-3OH-kinase (PI3K) (RodriguezViciana et al., 1997) , protein Kinase C (Diaz-Meco et al., 1994) , MEKK1 (Russell et al., 1995) , RalGDS and RGL (White et al., 1996) .
Small GTP binding proteins act through a variety of intracellular signalling pathways, some of which interfere with myogenic dierentiation. For instance, overexpression of mutated Ras, Rho, Rac, Cdc42 and Rap proteins inhibits myotube formation (Olson et al., 1987; Takano et al., 1998; Pizon et al., 1999) . Interestingly, Raf and RalGDS proteins which are common eectors of the Ras and Rap proteins, are also potent inhibitors of myogenic dierentiation (Dorman and Johnson, 1999; Ramocki et al., 1998) . Although Rap1 protein function remains unclear, several observations indicate that Rap1 is involved in signal transduction (Bos, 1998) . Activated (GTPbound) Rap1 inhibits Ras-dependent LPA activation of ERK (Cook et al., 1993) and at least three second messengers (namely calcium, diacylglycerol and cAMP) can activate Rap1 in dierent cell types (Franke et al., 1997; Altschuler et al., 1995; Dremier et al., 2000) . In addition, a growing body of evidence supports the idea that Rap1 could interfere with MAP kinase pathways by trapping Raf protein (Boussiotis et al., 1997; Okada et al., 1998; Vossler et al. 1997) . During skeletal myogenic dierentiation, we previously observed that overexpression of the constitutively activated (GTPbound) Rap1A protein inhibits myoblastic dierentiation whereas the inactivated GDP-bound form of Rap1A favours myotube formation (Pizon et al., 1999) . In this study, we examined the possibility that in skeletal muscle cells, the phenotypes prompted by overexpression of mutated Rap1A proteins could be related to various MAP kinase pathways. Therefore, we investigated the contribution of Rap1A protein in MEK and ERK activation under normal growth conditions. Although overexpression of both activated or inactivated Rap1A proteins led to prolonged activation of ERK kinase, we found that the duration of the sustained ERK activation mediated by the GTPbound form of the protein was increased compared to the one induced by the GDP-bound form. We also observed that depending on its activated/inactivated state, Rap1A protein could interfere with dierent MAP kinase pathways in myogenic cells.
Results

GDP-and GTP-bound Rap1A protein induces ERK activation in myoblasts
According to the cell system analysed, Rap1 proteins could act either as an inhibitor or as an activator of the MAPK signalling pathway (Cook et al., 1993; Crespo et al., 1994; Boussiotis et al., 1997; Vossler et al., 1997; York et al., 1998; Zwartkruis et al., 1998) . Therefore, we examined whether overexpression of mutant Rap1A proteins in¯uences MAPK (ERK1 and 2) phosphorylation in proliferating myoblasts. To avoid clonal eects, we analysed two stable myoblastic cell lines expressing in a tetracycline (Tet) regulated manner, either GTP-bound (RapV12) or GDP-bound (RapN17) mutant Rap1A proteins (Pizon et al., 1999) . Figure 1 shows the results of Western blot analysis performed with equal quantities of cell extracts that only allowed detection of the ectopic Rap1 proteins. As expected, due to their rapid inactivation by phosphatases (Camps et al., 1999) , activated ERK proteins were barely detectable in proliferating control myoblasts ( Figure  1a , Ct). As observed previously (Pizon et al., 1999) , owing to leakage of the expression system, ectopic Rap protein synthesis was not completely abolished although cell culture medium contained Tet ( Figure  1b ). Compared to control cells, higher amounts of active ERK proteins were detected in RapN17 and RapV12 cells grown in the presence of Tet. However, in the absence of the drug, when mutated Rap1A proteins were expressed at the highest level (Figure 1b ) phosphorylated ERK proteins increased signi®cantly ( Figure 1a ). Since ERK phosphorylation followed the expression of ectopic Rap1A mutant proteins, we concluded that Rap1A protein could interfere with ERK activation pathways in proliferating myoblasts.
Overexpression of RAP1A mutant proteins extends the duration of ERK activation When they are stimulated by growth factors, many cell lines show a biphasic time course of MAPK activation. Five to ®fteen minutes after stimulation a ®rst burst of activation is detected. This ®rst burst of activation, known as transient MAPK activation, is followed by a later activation, known as sustained MAPK activation, which can last a few hours. Since Rap1 protein mediates sustained MAPK activation in PC12 cells (York et al., 1998) , we evaluated the duration of ERK activation in the dierent myogenic cell lines. In quiescent cells, before stimulation (Figure 2a, t=0 ) phosphorylated ERK proteins were barely detectable in control cells whereas RapN17 (17/1) and RapV12 (12/ 9) cells displayed low basal ERK activation. After stimulation by 10% foetal calf serum (FCS) for 5 min to 1 h, all the tested cells displayed ERK1 and ERK2 phosphorylation. In control cells, ERK activation was barely detectable after 1 h (Figure 2a) . In contrast, MAPK remained active until 2 h in cells overexpressing the mutated Rap proteins (Figure 2a ). When cells were stimulated for longer times, ERK activation diminished after 2 h in the 17/1 cells and remained high in the 12/9 cells even after 4 h of stimulation (Figure 2b) . Variation of the phosphorylated forms of ERK did not result from dierences in the amount of MAPK protein present in each extract, as observed by reprobing the Western blot with a pan-ERK antibody (Figure 2a ,b, lower panels). Similar results were obtained with the 17/ 8 and 12/12 cell lines, con®rming that our data were not due to clonal artifacts (data not shown).
Altogether, these data show that in response to 10% FCS myoblasts overexpressing mutant Rap1A proteins display prolonged ERK activation, the GTP-bound protein inducing a longer activation than the GDPbound form.
Analysis of the involvement of PI3K and MEK in transient MAPK activation
ERK proteins can be activated by a wide variety of signals. In addition to the Ras/Raf/MEK-dependent MAPK pathway (Widmann et al., 1999) , PI3K seems to play a major role in the MEK-independent prolonged MAPK activation (Milasincic et al., 1996; Grammer and Blenis, 1997; Takeda et al., 1999 ). Thus we examined the possible role of MEK and PI3K in regulating transient ERK activation. To address this question, we used a synthetic speci®c inhibitor (PD098059) of MEK activation by Raf protein (Alesi et al., 1995) and wortmannin, a fungal metabolite that inhibits PI3K (Yano et al., 1993) . Compared to the activation observed in the absence of inhibitors, control and 17/1 cells treated with PD098059 displayed a decrease of ERK phosphorylation. Thus a Raf/MEK pathway could be in part responsible for ERK activation (Figure 3) . Surprisingly, PD098059 showed very limited eect on MEK activation, suggesting that an additional, Raf-independent pathway could also activate MEK. In agreement with this hypothesis, PI3K inhibition by wortmannin strongly inhibited MEK activation and prevented ERK activation by an extent similar to the one observed after PD098059 treatment. Since ERK activation was not completely inhibited after MEK inactivation, an additional pathway should directly contribute to ERK activation. Used together, the two inhibitors fully prevent ERK and MEK phosphorylation (data not shown). In RapV12 cells, both PD098059 and wortmannin completely abolish ERK and MEK phosphorylation. This complete inhibition by either inhibitor indicated that, in RapV12 cells, ERK activation occurred by a MEK-dependent signalling pathway and that PI3K could be the major regulator of MEK activation. Using a pan-ERK antibody we veri®ed that These data show that, according to its GDP-or GTP-bound form, Rap1A protein can interfere with distinct signal transduction pathways leading to transient ERK and MEK activation. In addition, the basal ERK activation mediated by Rap1A protein overexpression occurs by a MEK-independent pathway in quiescent cells.
Rap1A does not interfere with FCS-induced sustained MAPK activation
Involvement of MEK and PI3K was further investigated during sustained ERK activation. Quiescent cells were switched for 1 h to growing medium containing 10% FCS supplemented with PD098059 or wortmannin. Control myoblasts were stimulated for 1 h in growing medium containing 10% FCS and the same volume of DMSO used to dissolve the inhibitors. Western blot analysis revealed that all the cells showed identical patterns of ERK activation regardless of Rap1A expression (Figure 4) . Compared to the amount of phosphorylated ERK protein detected after 1 h of stimulation, pre-treatment of the cells with PD098059 led to an evident inhibition of ERK phosphorylation. In contrast, wortmannin did not display any major eect on ERK activation in all the tested cells.
These results indicate that Rap1A protein does not interfere with the sustained phase of ERK activation in myoblasts. Although an unidenti®ed Raf/MEK-and PI3K-independent pathway can slightly activate ERK proteins, sustained activation appears mediated mainly by a Raf/MEK-dependent pathway.
Mutant Rap1A proteins mediate different MAPK pathways in growing myoblasts
Since proliferating RapN17 and RapV12 myoblasts displayed prolonged ERK activation, we analysed the (Coughlin et al., 1985) . If PKC was implicated in MAPK activation, its down-regulation should prevent MEK and ERK phosphorylation. Figure 6a shows that PKC down-regulation led to similar decreases of MEK and ERK transient activation in control and RapN17 cells. In RapV12 cells, neither MEK nor ERK phosphorylation was aected by PKC inhibition. In contrast to transient activation, sustained ERK activation remained insensitive to chronic phorbol ester treatment in the tested cell lines (Figure 6b ). In quiescent myoblasts, short term TPA treatment activates MEK kinase (Campbell et al., 1995 and Figure 7 ). Since addition of TPA after PKC downregulation did not activate MEK in quiescent control and Rap17 cells, we assumed that our results did not result from incomplete PKC inhibition. Unresponsiveness to PKC down-regulation observed in RapV12 cells could re¯ect either the inactivity of PKC or the absence of response to TPA in these cells. To address this question, PKC activation was tested after short TPA treatment (Mellor et al., 1998) . Independently of FCS, TPA activated MEK and ERK proteins in all the cells (Figure 7) . However, the magnitude of MEK and ERK activation did not appear proportional. Compared to the phosphorylation mediated by FCS alone, TPA stimulated MEK at an extent greater than for ERK. Although surprising, an identical observation was reported for MM14 myoblastic cells (Campbell et al., 1995) . Since the basal ERK activation observed in unstimulated quiescent myoblasts overexpressing Rap1A mutant proteins was unrelated to MEK stimulation (Figures 3 and 6 ), we concluded that this basal ERK activation is not mediated by TPA-sensitive PKC.
Altogether, these results show that the tested cells contain functional TPA-sensitive PKC and that PKC partially mediates MEK and ERK transient activation in control and RapN17 cells but not in RapV12 cells.
Involvement of cAMP in MAPK activation
Various stimuli leading to a rise of intracellular cAMP activate Rap1A protein (Altschuler et al., 1995) . However, activation of Rap1A protein by cAMP is not speci®c to a transduction pathway and appears to be cell type-dependent. Therefore, we examined whether cAMP could aect MAPK activity in control, RapN17 and RapV12 cells. In all the cell lines, treatment with 8-bromo-cAMP resulted in ERK stimulation in quiescent cells (Figure 8 ). However, only quiescent RapV12 and RapN17 cells displayed increased MEK phosphorylation. After FCS stimulation, 8-bromo-cAMP treatment did not induce further activation of MEK or ERK kinase in all the tested cells. These results indicate that regardless of Rap1 protein expression, cAMP does not participate in MAP kinases activation after FCS stimulation. In contrast, in quiescent myoblasts Rap1A proteins interfere with a cAMP-dependent pathway triggering MEK activation.
Discussion
Overexpression of constitutively activated Rap1A protein (RapV12) inhibits myogenic dierentiation, whereas expression of inactivated Rap1A (RapN17) favours dierentiation (Pizon et al., 1999) . Since Rap1 proteins seem involved in various signal transduction pathways, leading to ERK activation or inactivation in dierent cell types, we wondered whether Rap1A mutants could trigger signal transduction cascades in skeletal muscle cells. Using cell lines overexpressing either RapV12 or RapN17 mutant proteins we report evidence indicating that both mutants prompted activation of ERK kinases in growing myoblasts. Moreover, ERK activation induced by RapV12 protein was at least two times longer than the one mediated by Figure 5 Eect of PD098059 and wortmannin on ERK activity in growing cells. Control, RapV12 and RapN17 myoblasts maintained in growing medium were treated with PD098059 or wortmannin. Thirty mg total protein was resolved by SDS ± PAGE. Speci®c anti-phosphorylated ERK antibody and pan-ERK antibody were successively used on the same Western blot. Two separate experiments showed similar results Eect of short-term TPA treatment on ERK and MEK activation. Quiescent control, RapV12 and RapN17 cells (1% FCS) were switched for 5 min to growing medium (10% FCS) with (+) or without (7) TPA. Western blot analysis was performed with 30 mg total protein using anti-phosphorylated ERK or MEK antibodies and with pan-ERK or pan-MEK antibodies. Two independent experiments showed similar results Figure 8 Involvement of cAMP in MAP kinases activation. Quiescent control, RapV12 and RapN17 cells (1%) were either left untreated (7) or pretreated (+) with 8-bromo-cAMP prior to 5 min stimulation with growing medium (10% serum) containing (+) or not (7) cAMP. Western blot analysis was performed with 20 mg total protein using anti-phosphorylated ERK or MEK antibodies. Equal amount of loaded protein was revealed by red Ponceau staining of the membrane used to reveal phosphorylated ERK proteins. The results are representative of three experiments Rap1A and MAP kinase activation in myogenic cells V Pizon and G Baldacci the RapN17 protein. In PC12 cells, nerve growth factor leads to Rap1A-dependent sustained MAP kinase activation and cell dierentiation (York et al., 1998) . In these cells, RapN17 blocks only the sustained ERK activation without inhibiting cell dierentiation. Therefore, Rap1A could regulate the timing of MAPK activation during PC12 cell dierentiation (McCawley et al., 1999) . Although the role of the MAPK pathway in regulating proliferation and dierentiation of muscle cells remains controversial, MAPK seem to play either positive or negative roles during dierentiation. At early stages, myoblasts overexpressing MAPK phosphatase-1 (MKP1) show enhanced production of muscle-speci®c proteins, suggesting that activated MAPK play a negative role at the beginning of dierentiation. Later, overexpression of MKP1 inhibits myotube formation indicating that MAPK activation is needed to accomplish myogenesis (Bennett et al., 1997) . In addition, expression of rVH6, a cytosolic phosphatase implicated in MAPK inactivation, is higher in proliferating MM14 myoblasts than in dierentiated cells (Mourey et al., 1996) . Thus, myogenic dierentiation seems in part dependent on the timing of MAPK activation. In this regard, and according to the results reported with PC12 cells, the eects induced by overexpression of RAP1A mutants on MAPK activation could be correlated with opposite eects on myogenic dierentiation. The sustained MAPK activation mediated by RapV12 protein could prevent the inactivation of MAPK needed for the progression of the myogenic program. In contrast, RapN17 protein could promote myotube formation by interfering at an earlier stage of dierentiation. In agreement with this hypothesis, we previously reported that during myogenic dierentiation maximum amount of GDP-and GTP-bound endogenous Rap1A protein were detected at the time of cell fusion and in myotubes, respectively (Pizon et al., 1999) .
In addition to the kinetics of MAPK activation, the nature of the signalling pathways might also be important to mediate speci®c cellular responses. In MM14 myoblasts, ®broblast growth factors (FGFs) and platelet growth factor (PDGF-BB) are both able to stimulate MAPK, however FGFs inhibit skeletal muscle dierentiation when PDGF-BB elicits no detectable eect (Kudla et al., 1995) . By analysing the contribution of MEK and PI3K during transient ERK activation, we showed that in control and RapN17 myoblasts, ERK activation was mediated by at least three dierent pathways: a Raf/MEK-dependent pathway, a PI3K/Raf-independent pathway that strongly activates MEK and a third undetermined pathway that directly activates ERK proteins. Consistent with the notion that PKC acts downstream of PI3K, in control and in RapN17 cells, TPA sensitive PKC can trigger MEK activation in a PI3K-dependent pathway. In RapV12 cells transient ERK activation occurred only by a PI3K/Raf/MEK-dependent signalling pathway. This PI3K-dependent pathway seems independent of TPA-sensitive PKC proteins since PKC down-regulation did not aect either MEK or ERK activation. Although the precise mechanism(s) deregulated in RapV12 myoblasts remain to be de®ned, it is noteworthy that these cells display a speci®c MAPK activating pathway and are impeded in their dierentiation program. Interestingly, accumulating evidence suggests that PI3K is neither necessary for cell proliferation nor for initial events of myoblast dierentiation but is essential for terminal dierentiation of myotubes (Kaliman et al., 1996; Pinset et al., 1997) .
In contrast with the results obtained in growing cells and during transient activation, sustained ERK activation is not related to Rap1 protein expression. Sustained activation of MAPK occurs mainly by a Raf/MEKdependent pathway independent of PI3K and TPAsensitive PKC enzymes. Thus, in growing cells, Rap1A mutants could promote prolonged ERK activation by interfering with the duration and with the signalling transduction cascade of the ®rst transient ERK activation, not by deregulating the sustained ERK activation. In quiescent cells, TPA is a potent activator of ERK and acts at the MEK level. Since quiescent RapN17 and RapV12 cells displayed MEK-independent ERK activation, this activation is not mediated by a TPA-sensitive PKC pathway. We also showed that after rapid stimulation by FCS, cAMP activated MEK and ERK proteins independently of Rap1A expression in myoblasts. In contrast, cAMP enhances MEK activation in quiescent cells overexpressing both Rap1A mutants. Therefore, we propose that in quiescent cells cAMP could aect the phosphorylation rather than the activation of Rap1A protein (Lapetina et al., 1989; Lerosey et al., 1991; Hu et al., 1999) .
How could RapN17 mutant interfere with myogenic dierentiation? Controversial results have been reported about the function of the RapN17 protein as a dominant-negative mutant. Nevertheless, expression of RapN17 interferes with ERK activation in PC12 cells (York et al., 1998) , abolishes the CD31 receptordependent adhesion of Jurkat cells (Reedquist et al., 2000) and induces clustering of late endocytic compartments in myoblasts (Pizon et al., 1999) . These data indicate that RapN17 is able to ful®l speci®c biological functions. Although RapN17 did not display speci®c eects on transient MAPK activation, quiescent myoblasts overexpressing the GDP-bound protein diered in their basal MEK-independent ERK activation. Moreover, upon growth conditions, the RapN17 protein seems to interfere speci®cally with ERK activation and to perform an antagonist eect on a PI3K-dependent pathway. Since PI3K is involved in membrane tracking between late endosomes and lysosomes (Kundra et al., 1998) and since overexpression of RapN17 induces clustering of the late endocytic compartments in myoblasts, RapN17 could prompt redistribution of late endocytic compartments by interfering with a PI3K-dependent transduction pathway.
Altogether, our results illustrate the complexity of ERK and MEK pathways in myogenic cells and the complexity of the mechanisms by which the small GTP-binding protein Rap1A interferes with their activation.
Materials and methods
Reagents
Tissue culture media and media additives were purchased from Gibco BRL. Foetal calf serum (FCS) was from D Dutsher Inc. Wortmannin, 12-O-tetradecanoylphorbol 13-acetate (TPA), dimethyl sulphoxide (DMSO), bovine serum albumin (BSA), 8-bromo-cAMP, tetracycline hydrochloride (Tet) were purchased from Sigma. PD098059 was from Calbiochem Inc.
Cell culture
Myoblastic cells were grown as described previously (Pizon et al., 1999) . For MAP kinase assays, quiescent myoblasts were obtained by keeping 80% con¯uence cells in DMEM medium supplemented with 1% FCS for 16 h. When needed, cells were treated either with 1 mM wortmannin for 30 min or 1 h in order to inhibit PI3K, or with 50 mM PD098059 for 1 h to inhibit MEK. PKC activation was obtained by treating the cells with (100 ng/ml) TPA for 5 min. PKC down-regulation was performed by TPA treatment (100 ng/ml) for 16 h. When wortmannin, PD098059 or TPA were used, control cells were pre-treated for the same time and with the same volume of vehicle (DMSO). 8-bromo-cAMP was used at 0.5 mM for 10 min. Stimulation was carried out by switching the cells in DMEM medium containing 10% FCS for the times indicated in the ®gure legends.
Protein extracts and immunoblotting
Cells washed with cold PBS were scraped in tissue culture dishes with lysing buer containing 50 mM Tris, pH 8, 20 mM EDTA, 1% SDS, 1 mM PMSF, 10 mg/ml leupeptin and apoprotinin, 1 mg/ml pepstatin, 50 mM NaF and 1 mM NaVo4. Cell lysates were then heated for 10 min at 958C and protein concentration determined by the Pierce Micro BCA protein assay system according to the supplier's protocol. Proteins were resolved on 12% SDS-polyacrylamide gel (SDS ± PAGE) and transferred onto 0.2 mm Trans-Blot membrane (Bio-Rad). Filters pre-washed for 1 h at room temperature in PBS containing 0.1% Tween-20 and 3% BSA were incubated overnight with primary antibody at 48C. After washes with PBS containing 0.1% Tween-20, membranes were incubated with proper secondary antibody for 1 h at room temperature. Immunoreactive signals were revealed by the chemiluminescence protocol (Amersham). When needed, membranes were stripped o before reprobing according to the manufacturer's instructions (Amersham). Anity-puri®ed Rap1A antibody was prepared as described previously (Pizon et al., 1994) . Speci®c anti phosphorylated-ERK or -MEK antibodies were purchased from New England Biolabs and anti pan-ERK or -MEK antibodies were from Santa Cruz Inc.
